Editorial Material
Endocrinology & Metabolism
Michael B. Stout, Rebecca L. Scalzo, Elizabeth A. Wellberg
Summary: Tamoxifen, a selective estrogen receptor modulator, is commonly used in preclinical studies and treatment of ER-positive breast cancer. Activation of Cre-ER transgenes in mice requires tamoxifen administration through various methods and doses, leading to inconsistent metabolic effects compared to anecdotal reports and expected outcomes.
Article
Biochemistry & Molecular Biology
Alok Mishra, Anshuman Srivastava, Ankit Pateriya, Manendra Singh Tomar, Anand Kumar Mishra, Ashutosh Shrivastava
Summary: Breast cancer is the most common cancer among females, and endocrine therapy for ER-positive breast cancer can result in acquired resistance. The metabolic state of cancer cells plays a crucial role in their susceptibility to chemotherapeutic drugs, and understanding metabolic pathway alterations in TAMR cancer may offer potential therapeutic strategies.
CHEMICO-BIOLOGICAL INTERACTIONS
(2021)
Article
Pharmacology & Pharmacy
Faten Shehadeh-Tout, Heloisa H. Milioli, Suraya Roslan, Patric J. Jansson, Mahendiran Dharmasivam, Dinny Graham, Robin Anderson, Tharushi Wijesinghe, Mahan Gholam Azad, Des R. Richardson, Zaklina Kovacevic
Summary: This study investigates a new class of anti-cancer agents for the treatment of ER-positive breast cancer. These agents inhibit multiple growth factor receptors and down-stream signaling, leading to decreased expression of hormone receptors and key resistance pathways. In vivo experiments demonstrate that these agents effectively inhibit ER-positive breast cancer growth. This represents an innovative non-hormonal, multi-modal therapeutic approach.
PHARMACOLOGICAL RESEARCH
(2023)
Review
Oncology
Nivida Shete, Jordan Calabrese, Debra A. Tonetti
Summary: Estrogen is a key driver of estrogen-receptor-positive breast cancers, and drugs that block estrogen signaling are commonly used for treatment. Surprisingly, estrogen was previously used to treat breast cancer before the introduction of tamoxifen. This review focuses on the insights, molecular mechanisms, and potential clinical application of this counterintuitive therapeutic approach.
Article
Biochemistry & Molecular Biology
Chih-Jung Chen, Ting-Hao Chen, Jason Lei, Ji-An Liang, Po-Sheng Yang, Chiun-Sheng Huang, Chia-Ming Hsieh, Ling-Ming Tseng, Liang-Chih Liu, Skye Hung-Chen Cheng, Kuan-Hui Shih
Summary: This study compared the biomarker expression and breast cancer subtyping results obtained by immunohistochemistry (IHC) and reverse transcriptase-polymerase chain reaction (RT-PCR). The results showed concordance between the two methods, and RT-PCR performed similarly to IHC in predicting 5-year survival.
BIOSCIENCE REPORTS
(2022)
Article
Pathology
Keying Xu, Jane Bayani, Elizabeth Mallon, Gregory R. Pond, Tammy Piper, Annette Hasenburg, Christos J. Markopoulos, Luc Dirix, Caroline M. Seynaeve, Cornelis J. H. van de Velde, Daniel W. Rea, John M. S. Bartlett
Summary: Based on quantitative molecular analysis of breast cancers using RNA expression, this study found that the dynamic range of HER2 expression in HER2-low expressing breast cancers exceeds the detection range of current immunohistochemistry methods. It suggests that defining HER2-low cancers based on RNA abundance may better serve treatment decision needs. However, further evaluation through prospective clinical trials is needed to validate the efficacy of RNA abundance in identifying HER2-low cancers and predicting treatment response.
JOURNAL OF MOLECULAR DIAGNOSTICS
(2022)
Article
Clinical Neurology
Carmen M. Avram, Barbara H. Brumbach, Amie L. Hiller
Summary: The findings suggest that exposure to tamoxifen in women with breast cancer may increase the risk of Parkinson's disease, but overall rates of PD in this population appear to be low. Further research is needed to clarify the role of estrogen and selective estrogen antagonism in PD.
MOVEMENT DISORDERS
(2021)
Article
Microbiology
Hernando Gutierrez-Barbosa, Sandra Medina-Moreno, Federico Perdomo-Celis, Harry Davis, Carolina Coronel-Ruiz, Juan C. Zapata, Joel V. Chua
Summary: Humanized mice are valuable for studying human diseases, but it is important to understand their strengths and limitations and choose the appropriate model. This study found that the Hu-SGM3 model consistently produced higher numbers of various human immune cells, while the hu-NOG-EXL model had a higher number of circulating platelets in an inactivated state. The hu-NSG and hu-NCG models had low frequencies of immune cells. Therefore, selecting the right humanized mouse model is crucial for specific research questions.
Article
Medicine, Research & Experimental
Coralie Poulard, Thuy Ha Pham, Youenn Drouet, Julien Jacquemetton, Ausra Surmielova, Loay Kassem, Benoite Mery, Christine Lasset, Jonathan Reboulet, Isabelle Treilleux, Elisabetta Marangoni, Olivier Tredan, Muriel Le Romancer
Summary: Endocrine therapies targeting estrogen signaling have improved management of estrogen receptor alpha (ERα)-positive breast cancers. However, resistance to treatment remains a challenge. This study identifies nuclear PRMT5 expression as a predictive marker of sensitivity to tamoxifen in breast cancer patients, and reveals the mechanism of tamoxifen stimulating ERα methylation by PRMT5. This biomarker could be used to enhance response to tamoxifen in ERα-positive breast tumors.
EMBO MOLECULAR MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Kiminori Ohta, Asako Kaise, Takumi Ogawa, Yasuyuki Endo
Summary: In this study, a novel estrogen receptor modulator Az-01 was developed as an alternative to tamoxifen for breast cancer treatment. Az-01 exhibited similar estrogen receptor binding affinity to tamoxifen, but acted as a partial agonist and showed potent anti-estrogenic activity in the presence of estrogen. Furthermore, Az-01 demonstrated specific cell proliferation and inhibition activities in ER-expressing cells without affecting other cell proliferation signals.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Chenglin Lu, Ji Miao, Minhuan Li, Qisi Zheng, Feng Xu, Yiming Pan, Yizhou Wang, Zhi Yang, Xuefeng Xia, Hao Zhu, Jie Chen, Shanhua Bao
Summary: This study reveals the correlation between estrogen response and prognosis in cholangiocarcinoma (CCA). CCA was classified into two clusters based on estrogen response, and COMT and HSD17B1 were identified as responsible factors for the differential estrogen response between the clusters. An estrogen response risk score (ESRS) model was constructed for prognostic prediction, and altered pathways, applicable drugs, and drug sensitivity were analyzed specific to the estrogen response.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Sarita Singh, Surendra Chandra Verma, Vinay Kumar, Kriti Sharma, Diksha Singh, Sana Khan, Neelam Gupta, Romila Singh, Feroz Khan, Debabrata Chanda, Durga Prasad Mishra, Divya Singh, Partha Roy, Atul Gupta
Summary: This study presents a series of amide derivatives based on 3-aryl-3H-benzopyran that exhibit osteogenic and anticancer activities. Compound 24b showed significant osteogenic activity and effectively inhibited the growth of osteosarcoma and breast cancer cells. Mechanistic studies revealed that 24b induced apoptosis and inhibited cancer cell migration.
BIOORGANIC CHEMISTRY
(2023)
Review
Pediatrics
Ahila Ayyavoo
Summary: Enlargement of breasts among boys, known as gynecomastia, can be caused by changes in the androgen-estrogen ratio and the effects of various hormones. Factors such as puberty, obesity, drugs, and hypogonadism can contribute to gynecomastia. Other conditions including liver or renal failure, thyrotoxicosis, Klinefelter syndrome, tumors, and environmental pollutants can also cause gynecomastia. Medical management, including hormone therapy, is often effective in mild cases, while surgery may be necessary for severe and chronic gynecomastia.
INDIAN JOURNAL OF PEDIATRICS
(2023)
Article
Biochemistry & Molecular Biology
Hye Hyeon Yun, Soon Young Jung, Bong Woo Park, Ji Seung Ko, Kyunghyun Yoo, Jiyoung Yeo, Hong Lim Kim, Hun Jun Park, Ho Joong Youn, Jeong Hwa Lee
Summary: The study developed tamoxifen-inducible cardiomyocyte-specific BIS-KO mice and found that disruption of the Bis gene led to impaired heart function and heart failure. These mice may serve as a useful model for developing therapeutic interventions for dilated cardiomyopathy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cell Biology
Ingrid Espinoza, Lin Yang, Travis Vander Steen, Luciano Vellon, Elisabet Cuyas, Sara Verdura, Lester Lau, Javier A. Menendez, Ruth Lupu
Summary: CCN1 promotes angiogenesis, tumor growth, and chemoresistance in endothelial and breast cancer cells by binding to its integrin receptor α(v)β(3). It also controls tissue regeneration by engaging its integrin receptor α(6)β(1) to induce fibroblast senescence. In estrogen receptor-positive breast cancer cells, CCN1 drives an endocrine resistance phenotype through its interaction with ER α.
Review
Chemistry, Medicinal
Chanitra Thuwajit, Alessandra Ferraresi, Rossella Titone, Peti Thuwajit, Ciro Isidoro
MEDICINAL RESEARCH REVIEWS
(2018)
Article
Oncology
Rochanawan Sootichote, Peti Thuwajit, Ekapot Singsuksawat, Malee Warnnissorn, Pa-thai Yenchitsomanus, Suthinee Ithimakin, Jomjit Chantharasamee, Chanitra Thuwajit
Article
Biophysics
S. Saesoo, S. Sathornsumetee, P. Anekwiang, C. Treetidnipa, P. Thuwajit, S. Bunthot, W. Maneeprakorn, L. Maurizi, H. Hofmann, Ruktanonchai Uracha Rungsardthong, N. Saengkrit
COLLOIDS AND SURFACES B-BIOINTERFACES
(2018)
Article
Oncology
Jumaporn Sonongbua, Suchada Siritungyong, Suyanee Thongchot, Thanpawee Kamolhan, Kusumawadee Utispan, Peti Thuwajit, Ananya Pongpaibul, Sopit Wongkham, Chanitra Thuwajit
Article
Oncology
Nuttavut Sumransub, Niphat Jirapongwattana, Pranisa Jamjuntra, Suyanee Thongchot, Thaweesak Chieochansin, Pa-Thai Yenchitsomanus, Peti Thuwajit, Malee Warnnissorn, Pornchai O-Charoenrat, Chanitra Thuwajit
Article
Oncology
Witchuda Sukjoi, Siraprapa Siritutsoontorn, Pakkanan Chansongkrow, Suppakit Waiwitlikhit, Steven W. Polyak, Malee Warnnissorn, Varodom Charoensawan, Chanitra Thuwajit, Sarawut Jitrapakdee
ANTICANCER RESEARCH
(2020)
Article
Cell Biology
Suyanee Thongchot, Ekapot Singsuksawat, Nuttavut Sumransub, Ananya Pongpaibul, Attaporn Trakarnsanga, Peti Thuwajit, Chanitra Thuwajit
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2020)
Article
Oncology
Khine Kyaw Oo, Thanpawee Kamolhan, Anish Soni, Suyanee Thongchot, Chalermchai Mitrpant, Pornchai O-charoenrat, Chanitra Thuwajit, Peti Thuwajit
Summary: The study developed an anti-PN peptide to inhibit proliferation, migration, and chemoresistance in breast cancer cells. Serum PN correlated with tissue PN expression, but not with clinical data.
Article
Gastroenterology & Hepatology
Varayu Prachayakul, Manus Rugivarodom, Papatsakorn Nopjaroonsri, Kunsuda Cheirsilpa, Thanpawee Kamolhan, Thiraphon Boonyaarunnate, Chanitra Thuwajit, Peti Thuwajit, Arunchai Chang
Summary: This study demonstrated that the methylation index of HOXA1 and NEUROG1 genes could improve the sensitivity and accuracy for the diagnosis of CCA. Combining methylation markers with brush cytology and CA19-9 further increased diagnostic power. DNA methylation shows promising potential for the diagnosis of CCA in patients with biliary strictures, warranting further validation studies for clinical application.
GASTROINTESTINAL ENDOSCOPY
(2022)
Review
Immunology
Jarupa Soongsathitanon, Pranisa Jamjuntra, Nuttavut Sumransub, Supaporn Yangngam, Marjorie De la Fuente, Glauben Landskron, Peti Thuwajit, Marcela A. Hermoso, Chanitra Thuwajit
Summary: Signals from the tumor microenvironment can influence cancer progression significantly, with immune cells and CAFs playing crucial roles in modulating tumor growth. The interaction between CAFs and tumor-infiltrating immune cells may serve as a potential therapeutic target for regulating the immunosuppressive microenvironment in breast cancer.
JOURNAL OF IMMUNOLOGY RESEARCH
(2021)
Article
Oncology
Suyanee Thongchot, Niphat Jirapongwattana, Piriya Luangwattananun, Wannasiri Chiraphapphaiboon, Nisa Chuangchot, Doonyapat Sa-Nguanraksa, Pornchai O-Charoenrat, Peti Thuwajit, Pa-Thai Yenchitsomanus, Chanitra Thuwajit
Summary: The study showed that high levels of nucleolin (NCL) and programed death-ligand 1 (PD-L1) in TNBC patients are associated with the worst clinical outcomes. Activating NCL-specific T cells can lead to effective killing of TNBC cells.
MOLECULAR CANCER THERAPEUTICS
(2022)
Review
Genetics & Heredity
Supaporn Yangngam, Jaturawitt Prasopsiri, Phimmada Hatthakarnkul, Suyanee Thongchot, Peti Thuwajit, Pa-thai Yenchitsomanus, Joanne Edwards, Chanitra Thuwajit
Summary: This study conducted a meta-analysis to evaluate the prognostic value of nucleolin (NCL) in different subcellular localizations in various cancers. The results showed that high total NCL and cytoplasmic NCL were associated with poor overall survival and short disease-free survival, while high nuclear NCL was correlated with increased patient overall survival.
JOURNAL OF MOLECULAR MEDICINE-JMM
(2022)